Alder Biopharmaceuticals Inc (ALDR)

Trade ALDR now with
10/10/2019 8:10:21 AM Alder BioPharma Announces First-in-Human Dosing In Phase 1 ALD1910 Study For Preventive Treatment Of Migraine
9/16/2019 2:08:57 AM Lundbeck To Acquire Alder In Transaction Valued At Up To $1.95 Bln
7/11/2019 8:06:09 AM Alder BioPharma Says Data From Post-hoc Analyses Of PROMISE-1 And PROMISE-2 Phase 3 Clinical Trials For Eptinezumab
1/17/2019 4:08:55 PM Alder BioPharmaceuticals Appoints Paul Streck As Chief Medical Officer
12/11/2018 4:05:48 PM Alder BioPharmaceuticals Appoints Carlos Campoy As CFO
10/23/2018 8:21:03 AM Alder BioPharma Announces Positive Results From Pharmacokinetic Comparability Study For Eptinezumab
10/5/2018 4:06:08 PM Alder BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
6/29/2018 8:34:29 AM Alder BioPharma Says New 6-Month Data For Eptinezumab Demonstrating Improvement In Efficacy In PROMISE 2 Phase 3 Trial
6/29/2018 8:32:59 AM Alder Presents One-Year Data For Eptinezumab From PROMISE 1 Phase 3 Showing Long-Term Efficacy In Episodic Migraine
6/7/2018 8:09:27 AM Alder BioPharma Names Robert Azelby President And CEO
4/25/2018 8:40:55 AM Alder BioPharma Announces New Data From Its PROMISE 1 Phase 3 Clinical Trial Evaluating Eptinezumab
4/24/2018 8:36:20 AM Alder BioPharma Presents 12-Month Data Of Eptinezumab In PROMISE 1 Phase 3 Trial In Episodic Migraine Patients
4/23/2018 8:34:15 AM Alder BioPharma Appoints Eric Carter As Interim Chief Medical Officer